임상에서의 'VO2 at VAT' 값은 유데나필을 복용한 환자군에서 2.9% 향상된 반면 위약군에서는 1.0% 감소했다.
Clinically, the "VO2 at VAT" value was improved by 2.9% in the group administrating udenafil, and on the other hand, it was decreased by 1.0% in the placebo group.